Inhibrx Biosciences (INBX) News
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INBX news summary
We found 7 recent headlines mentioning Inhibrx Biosciences (INBX): 1 in the past week and 4 in the past 30 days, most often from PR Newswire, Nasdaq, Seeking Alpha. INBX is making an outsized move today, down 7.21% at $68.97, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma", was published by PR Newswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Inhibrx Biosciences headlines
- Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ --…PR Newswire
- Inhibrx Q3 Loss Widens(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical, on Friday reported a wider third-quarter loss, reflecting higher general and administrative expenses.Nasdaq
- Inhibrx Biosciences GAAP EPS of -$2.46 beats by $0.06, revenue of $2MSeeking Alpha
- Inhibrx Reports Third Quarter 2026 Financial ResultsSAN DIEGO, Nov. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical…PR Newswire
- Thursday 10/15 Insider Buying Report: INBXBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their…Nasdaq
- Inhibrx Announces Participation in Upcoming Scientific ConferencesSAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of…PR Newswire
- Thursday 9/24 Insider Buying Report: GME, INBXBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their…NasdaqGME, INBX